IDEAYA Biosciences Inc
IDYAHealthcare|Biotechnology|USA
$36.99
-0.29 (-0.78%)
Tangible Book
$10.67
Upcoming Data Readouts (10)
Oct 2026
Est. completion
P1Advanced or Metastatic Solid Tumors
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587n=216
Jan 2027
Est. completion
P1Solid Tumor
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
NCT04794699n=169
Jan 2027
Est. completion
P2P3Metastatic Uveal Melanoma
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332n=420
Jan 2027
Est. completion
P1P2Metastatic Uveal Melanoma
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
NCT03947385n=336
Apr 2027
Est. completion
P2Uveal Melanoma
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
NCT05907954n=160
Jul 2027
Est. completion
P1Esophageal Squamous Cell Carcinoma
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808n=150
Apr 2028
Est. completion
P1NSCLC Adenocarcinoma
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT07277413n=260
Jul 2029
Est. completion
P1P2Small-cell Lung Cancer
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583n=262
Mar 2030
Est. completion
P1ER+, HER 2- Breast Cancer
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
NCT07540572n=160
Oct 2030
Est. completion
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Jun 2026
P1P2
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT06710847